跳至主要内容
临床试验/EUCTR2017-003788-36-HU
EUCTR2017-003788-36-HU进行中(未招募)1 期

Safety and Efficacy of turoctocog alfa pegol (N8-GP) in Prophylaxis and Treatment of Bleeds in Previously N8-GP Treated Patients with Severe Haemophilia A - pathfinder8

ovo Nordisk A/S0 个研究点目标入组 170 人开始时间: 2018年2月14日最近更新:
适应症

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
170

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
Male

入选标准

  • 1. Male patients of all ages with the diagnosis of severe congenital haemophilia A (FVIII activity <1%) based on medical records
  • 2. On-going participation in NN7088-3859 (pathfinder2), or NN7088-3885 (pathfinder5) at the time of transfer
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range: 60
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 105
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 5

排除标准

  • 1. Known or suspected hypersensitivity to trial product including allergy to hamster protein or related products
  • 2. Any disorder, except for conditions associated with haemophilia, which in the investigator’s opinion might jeopardise patient’s safety or compliance with the protocol
  • 3. Current participation in any clinical trial (except NN7088-3859 (pathfinder2) or NN7088-3885 (pathfinder5)) of an approved or non-approved investigational medicinal product

研究者

相似试验

A research study looking at how a factor VIII... | 临床试验